Clinical Trial Update: A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab [Phase 2]

View source ↗

Summary

Phase 2 study evaluating irinotecan and cetuximab with or without IMC-A12 for colon or rectal cancer after progression on oxaliplatin and bevacizumab; the trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Rectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• IMC-A12 (cixutumumab)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Colon Cancer, Rectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-06-01